Calidi Biotherapeutics — Third Quarter 2026 Earnings Summary

Calidi Biotherapeutics reported a net loss of $3.6 million for the third quarter of 2026, a significant improvement from the $10.8 million loss in the same period of 2025. The company advanced its lead candidate CLD-401, presenting preclinical data at the ESMO Congress 2026 that demonstrated complete tumor eradication in 80% of mice in breast cancer models. General and administrative expenses decreased by 39% to $1.6 million as the firm executed a restructuring plan to extend its cash runway. Additionally, Calidi raised $1.2 million through an at-the-market registered direct offering and ended the quarter with $3.9 million in cash.